You are here

  • Home
  • Archive
  • Volume 3, Issue Suppl 2
  • Tetramer based approach for efficient identification and isolation of neo-antigen specific CD8 T cells from peripheral blood (PBL) of patients with metastatic cancers

Article Text

Article menu

Download PDFPDF

Poster Presentation
Tetramer based approach for efficient identification and isolation of neo-antigen specific CD8 T cells from peripheral blood (PBL) of patients with metastatic cancers
Free
  1. Mini Bharathan1,
  2. Katarina Trebska-McGowan2,
  3. Pasetto Anna2,
  4. Drew C Deniger1,
  5. Ken-ichi Hanada2,
  6. Jared J Gartner2,
  7. James C Yang3,
  8. Steven A Rosenberg1 and
  9. Paul F Robbins3
  1. Aff1 grid.48336.3a0000000419368075NIH/NCI Bethesda MD USA
  2. Aff2 grid.94365.3d0000000122975165NIH/NCI Surgery Branch Bethesda MD USA
  3. Aff3 grid.94365.3d0000000122975165National Institutes of Health Bethesda MD USA

https://doi.org/10.1186/2051-1426-3-S2-P47

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Meeting abstracts

    Background

    Adoptive cell therapy with T cells bearing mutation specific T cell receptors (TCR) can be an effective method for treating metastatic cancers. The objective of this study was to identify mutation reactive T cells in the circulation of patients with different types of metastatic cancer.

    Methods

    The strategy utilized whole exome sequencing data to identify somatic non-synonymous mutations and then in-silico algorithms to predict minimal epitopes encoding mutated amino acids for each patient specific HLA-allele. CD8-enriched PBL from each patient were stained with tetramers generated in house by a UV-exchangeable technique as previously described for A*02:01, A*03:01, A*11:01, B*07:02, and a commercial tetramer was acquired for B*57:01. Based on the initial staining frequency (+tetramer+ T cells recognizing 7 unique neo-antigens from the PBL of 4 patients (ranging from 1 to 4 per patient). We enriched the frequencies of CD8+tetramer+ cells from 0.5 to >85%, 0.3 to >65% and 0.01 to 3% from the PBL of patients with colorectal (3971-A*02:01), lung (4014-B*57:01), and ovarian (4067-B*07:02) cancers respectively, using individual tetramers. Populations reactive with three HLA-A*11:0-restricted and one HLA-A*03:01-restricted neoantigens were also isolated from the PBL of lung cancer patients 4014 and 4037, respectively, using a pooled tetramer approach.

    Results

    Overall, the isolated T cells recognized mutated epitopes when co-cultured with autologous CD14+ monocytes pulsed with mutated peptides in the context of appropriate MHC-I alleles including HLA-A*02:01, HLA-A*03:01, HLA-A*11:01, HLA-B*07:02, and HLA-B*57:01, with reactivity detected using IFN-γ ELISA. Using single cell PCR, we could clone the TCRs reactive with an HLA-*02:01-presented colon cancer neoantigen and an HLA-B*57:01-presented lung cancer neoantigen. Evaluation of PBL retrovirally-transduced with these TCRs demonstrated that they bound to tetramers and secreted IFN-γ when co-cultured with CD14+ monocytes pulsed with appropriate mutated peptides.

    Conclusions

    To conclude, tetramers offer a sensitive, fast and reliable methodology to isolate mutation specific tumor reactive T cells from PBL of cancer patients. Furthermore, this method facilitates the identification, and cloning of mutation reactive TCR with which to construct receptor-engineered T cells for adoptive T cell therapy.